Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Update

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) saw a significant growth in short interest in September. As of September 30th, there was short interest totaling 8,400 shares, a growth of 189.7% from the September 15th total of 2,900 shares. Based on an average daily volume of 11,900 shares, the short-interest ratio is presently 0.7 days. Based on an average daily volume of 11,900 shares, the short-interest ratio is presently 0.7 days.

Global X Genomics & Biotechnology ETF Stock Up 4.3%

NASDAQ:GNOM opened at $44.54 on Tuesday. The stock’s fifty day moving average is $38.39 and its two-hundred day moving average is $34.72. Global X Genomics & Biotechnology ETF has a 52 week low of $27.20 and a 52 week high of $44.64. The stock has a market capitalization of $54.34 million, a price-to-earnings ratio of -19.03 and a beta of 1.03.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Creative Financial Designs Inc. ADV acquired a new position in Global X Genomics & Biotechnology ETF during the first quarter worth $95,000. Halbert Hargrove Global Advisors LLC lifted its stake in Global X Genomics & Biotechnology ETF by 182.4% during the second quarter. Halbert Hargrove Global Advisors LLC now owns 13,685 shares of the company’s stock worth $115,000 after purchasing an additional 8,839 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in Global X Genomics & Biotechnology ETF by 18.5% during the first quarter. Smartleaf Asset Management LLC now owns 14,933 shares of the company’s stock worth $125,000 after purchasing an additional 2,329 shares in the last quarter. HighTower Advisors LLC lifted its stake in Global X Genomics & Biotechnology ETF by 16.7% during the first quarter. HighTower Advisors LLC now owns 15,242 shares of the company’s stock worth $121,000 after purchasing an additional 2,184 shares in the last quarter. Finally, Oxinas Partners Wealth Management LLC lifted its stake in Global X Genomics & Biotechnology ETF by 12.1% during the second quarter. Oxinas Partners Wealth Management LLC now owns 16,212 shares of the company’s stock worth $137,000 after purchasing an additional 1,751 shares in the last quarter. 56.95% of the stock is currently owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.